Leerink Partners Maintains Outperform on Axogen, Raises Price Target to $56
Leerink Partners analyst Mike Kratky maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $52 to $56.
Share
Why It Matters
A big finance expert thinks Axogen is a good company to watch. The expert raised their target price because they see promise ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.